0000950142-22-003233.txt : 20221121 0000950142-22-003233.hdr.sgml : 20221121 20221121175823 ACCESSION NUMBER: 0000950142-22-003233 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221021 FILED AS OF DATE: 20221121 DATE AS OF CHANGE: 20221121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hurvitz Chaim CENTRAL INDEX KEY: 0001630542 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38302 FILM NUMBER: 221406941 MAIL ADDRESS: STREET 1: C/O GALMED PHARMACEUTICALS LTD., 8 SHAUL STREET 2: HAMELECH BLVD, AMOT HAMISHPAT BLDG. CITY: TEL AVIV STATE: L3 ZIP: 64733 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NRX Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001719406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822844431 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1201 ORANGE STREET STREET 2: SUITE 600 CITY: WILMINGTON STATE: DE ZIP: 19801 BUSINESS PHONE: 484-254-6134 MAIL ADDRESS: STREET 1: 1201 ORANGE STREET STREET 2: SUITE 600 CITY: WILMINGTON STATE: DE ZIP: 19801 FORMER COMPANY: FORMER CONFORMED NAME: Big Rock Partners Acquisition Corp. DATE OF NAME CHANGE: 20171012 4 1 es220307158_4-hurvitz.xml OWNERSHIP DOCUMENT X0306 4 2022-10-21 0 0001719406 NRX Pharmaceuticals, Inc. NRXP 0001630542 Hurvitz Chaim C/O NRX PHARMACEUTICALS, INC. 1201 ORANGE STREET, SUITE 600 WILMINGTON DE 19801 1 0 0 0 Common Stock 2022-11-16 4 P 0 287812 0.99 A 287812 D Common Stock 2022-11-17 4 P 0 171780 1.08 A 459592 D Common Stock 2022-11-18 4 P 0 40408 1.10 A 500000 D Common Stock 1436350 I By Shirat HaChaim Ltd. Common Stock 208443 I By CH Health-Private Venture Capital Ltd. Employee Stock Option 0.75 2022-10-21 4 A 0 162660 A 2032-10-21 Common Stock 162660 381083 D The price reported above reflects the weighted average purchase price per share of common stock (the "Common Stock"), of NRx Pharmaceuticals, Inc. (the "Issuer"). The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for the Issuer. /s/ Chaim Hurvitz 2022-11-21